Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
1412 Views
eMediNexus 18 February 2018
Results from an observational multicenter study presented February 15, 2018 at the European Crohns and Colitis Organisation 2018 Congress in Vienna shows that vedolizumab improves mucosal healing in people with Crohns disease and ulcerative colitis who failed or became intolerant to previous anti-tumor necrosis factor (TNF) therapy.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
Low FT3: A Novel Potentially Modifiable Risk Factor for Diabetic Neu.....
How Anemia Types Alter HbA1c Values..
Optimizing Glycemic Control in GDM: Continuous Glucose Monitoring Vs C.....
Factors Driving the Atopic March in Children with Early-Onset Atopic .....
Metabolic Health: Another Piece in the Parkinson Puzzle?..
{{Article_Title}}..
South Asian Nations Push for Collaborative Public Health Research..
Health Ministry Mandates Excipient Disclosure on Drug Labels from 2026..
Israel to Perform World's First Human Spinal Cord Implant..
Madras High Court Seeks Report On Kidney Trafficking Racket in Tamil Nadu..
ICMR Study Shows Nutrition Support Cuts TB Risk, Influences WHO Policy..